{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:30:27Z","timestamp":1769023827725,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["CCNU25JC030"],"award-info":[{"award-number":["CCNU25JC030"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Hubei Province Natural Science Foundation","doi-asserted-by":"publisher","award":["2023AFB987"],"award-info":[{"award-number":["2023AFB987"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bioorg.2025.109433","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T15:58:46Z","timestamp":1766591926000},"page":"109433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Distribution- and metabolism-based drug discovery: SAR and SMR exploration of alkoxy-substituted vonoprazan derivatives as new potassium-competitive acid blockers"],"prefix":"10.1016","volume":"169","author":[{"given":"Yi","family":"Gong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-Wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Long","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan-Xing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Fu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.109433_bb0005","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/gut.2004.051821","article-title":"Epidemiology of gastrooesophageal reflux disease: a systematic review","volume":"54","author":"Dent","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.bioorg.2025.109433_bb0010","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0016-5085(00)70004-7","article-title":"Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome","volume":"118","author":"Wolfe","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bioorg.2025.109433_bb0015","first-page":"147","article-title":"How do NSAIDs cause ulcer disease? Bailliere's best practice & research","volume":"14","author":"Wallace","year":"2000","journal-title":"Clin. Gastroenterol."},{"key":"10.1016\/j.bioorg.2025.109433_bb0020","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.lpm.2016.04.012","article-title":"Prise en charge du gastrinome management of gastrinoma","volume":"45","author":"Hain","year":"2016","journal-title":"Presse Med."},{"key":"10.1016\/j.bioorg.2025.109433_bb0025","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1016\/j.bmc.2017.04.014","article-title":"Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action","volume":"25","author":"Nishida","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109433_bb0030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/236385a0","article-title":"Definition and antagonism of histamine H2 -receptors","volume":"236","author":"Black","year":"1972","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.109433_bb0035","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0005-2736(73)90035-7","article-title":"K+-stimulated ATPase in purified microsomes of bullfrog oxyntic cells","volume":"307","author":"Ganser","year":"1973","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bioorg.2025.109433_bb0040","doi-asserted-by":"crossref","first-page":"7690","DOI":"10.1016\/S0021-9258(17)32907-1","article-title":"A nonelectrogenic H+ pump in plasma membranes of hog stomach","volume":"251","author":"Sachs","year":"1976","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.109433_bb0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0005-2728(98)00041-3","article-title":"Evolution of P-type ATPases","volume":"1365","author":"Palmgren","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bioorg.2025.109433_bb0050","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2362.2005.01543.x","article-title":"Developments in the inhibition of gastric acid secretion","volume":"35","author":"Mossner","year":"2005","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2025.109433_bb0055","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev.pa.28.040188.001413","article-title":"Gastric H+, K+-ATPase as therapeutic target","volume":"28","author":"Sachs","year":"1988","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bioorg.2025.109433_bb0060","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0022-3565(25)23774-0","article-title":"Possible mechanism for the inhibition of gastric (H+, K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749","volume":"248","author":"Nagaya","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2025.109433_bb0065","doi-asserted-by":"crossref","first-page":"7800","DOI":"10.1021\/ja049607w","article-title":"Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors","volume":"126","author":"Shin","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2025.109433_bb0070","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00228-008-0538-y","article-title":"Proton pump inhibitors: an update of their clinical use and pharmacokinetics","volume":"64","author":"Shi","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109433_bb0075","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/290159a0","article-title":"Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+, K+)ATPase","volume":"290","author":"Fellenius","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.109433_bb0080","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/00042737-199911000-00016","article-title":"Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion","volume":"11","author":"Dammann","year":"1999","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bioorg.2025.109433_bb0085","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-2036.2000.00775.x","article-title":"Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole","volume":"14","author":"Katz","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2025.109433_bb0090","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1111\/j.1440-1746.2006.04717.x","article-title":"Nocturnal acid breakthrough: clinical significance and management","volume":"21","author":"Ang","year":"2006","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bioorg.2025.109433_bb0095","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2133\/dmpk.20.153","article-title":"Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies","volume":"20","author":"Furuta","year":"2005","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.bioorg.2025.109433_bb0100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2036.2005.02531.x","article-title":"Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next?","volume":"22","author":"Fass","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2025.109433_bb0105","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40261-016-0488-6","article-title":"Effect of multiple Oral doses of the potent CYP3A4 inhibitor clarithromycin on the pharmacokinetics of a single Oral dose of Vonoprazan: a phase I, open-label, sequential design study","volume":"37","author":"Jenkins","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.bioorg.2025.109433_bb0110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cpt.1059","article-title":"Response to \"CYP-mediated drug-drug interaction is not a major determinant of attenuation of antiplatelet function of clopidogrel by Vonoprazan\"","volume":"104","author":"Kagami","year":"2018","journal-title":"Clin. Pharmacol. Ther. (St. Louis, MO, U. S.)"},{"key":"10.1016\/j.bioorg.2025.109433_bb0115","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/apt.13588","article-title":"Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype","volume":"43","author":"Kagami","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2025.109433_bb0120","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2016.08.001","article-title":"Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases","volume":"168","author":"Inatomi","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2025.109433_bb0125","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bcp.2006.09.020","article-title":"Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+, K+-ATPase","volume":"73","author":"Gedda","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109433_bb0130","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1124\/jpet.107.120428","article-title":"Soraprazan: setting new standards in inhibition of gastric acid secretion","volume":"321","author":"Simon","year":"2007","journal-title":"J. Pharmacol. Exp. Therapeutics"},{"key":"10.1016\/j.bioorg.2025.109433_bb0135","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/(SICI)1099-081X(1998110)19:8<493::AID-BDD129>3.0.CO;2-Z","article-title":"Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats","volume":"19","author":"Han","year":"1998","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.bioorg.2025.109433_bb0140","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1124\/jpet.118.254904","article-title":"Effects of Tegoprazan, a novel potassium-competitive acid blocker, on rat models of gastric acid-related disease","volume":"369","author":"Kim","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2025.109433_bb0145","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1021\/jm300318t","article-title":"Discovery of a novel pyrrole derivative 1\u20135-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl -N-methylm ethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB)","volume":"55","author":"Arikawa","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109433_bb0150","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40265-023-01865-w","article-title":"Keverprazan hydrochloride: first approval","volume":"83","author":"Kang","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2025.109433_bb0155","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00228-023-03521-4","article-title":"Review of the clinical development of fexuprazan for gastroesophageal reflux\u2013related disease","volume":"79","author":"Ramani","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109433_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756283X17745776","article-title":"Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date","volume":"11","author":"Sugano","year":"2018","journal-title":"Therap. Adv. Gastroenterol."},{"key":"10.1016\/j.bioorg.2025.109433_bb0165","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4292\/wjgpt.v9.i7.63","article-title":"Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?","volume":"9","author":"Rawla","year":"2018","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2025.109433_bb0170","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/14656566.2017.1346087","article-title":"Vonoprazan fumarate for the management of acid-related diseases","volume":"18","author":"Martinucci","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.109433_bb0175","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.3389\/fphar.2018.01560","article-title":"Role of Vonoprazan in Helicobacter pylori eradication therapy in Japan","volume":"9","author":"Sugimoto","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109433_bb0180","first-page":"527","article-title":"Safety profile of vonoprazan compared with proton pump inhibitors: insight from a pharmacovigilance study","volume":"75","author":"Kambara","year":"2020","journal-title":"Pharmazie"},{"key":"10.1016\/j.bioorg.2025.109433_bb0185","doi-asserted-by":"crossref","DOI":"10.34133\/2022\/9852518","article-title":"Yang, distribution- and metabolism-based drug discovery: a potassium-competitive acid blocker as a proof of concept","volume":"2022","author":"Wang","year":"2022","journal-title":"Research"},{"key":"10.1016\/j.bioorg.2025.109433_bb0190","series-title":"Drug bioavailability. estimation of solubility, permeability, absorption and bioavailability. Series: Methods and Principles in Medicinal Chemistry","first-page":"146","volume":"43","author":"Gr\u00fcneberg","year":"2004"},{"key":"10.1016\/j.bioorg.2025.109433_bb0195","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1124\/jpet.111.179556","article-title":"A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals","volume":"337","author":"Hori","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2025.109433_bb0200","doi-asserted-by":"crossref","first-page":"15503","DOI":"10.1021\/acs.jmedchem.1c01539","article-title":"Discovery of next-generation tropomyosin receptor kinase inhibitors for combating multiple resistance associated with protein mutation","volume":"64","author":"Zhuo","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109433_bb0205","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1097\/00042737-199512000-00013","article-title":"Effects of anaesthetic agents on basal and histamine-stimulated acid secretion in the fistula rat","volume":"7","author":"Bastaki","year":"1995","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bioorg.2025.109433_bb0210","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejphar.2017.06.020","article-title":"KFP-H008 blocks gastric acid secretion through inhibiting H+\/K+-ATPase","volume":"810","author":"Li","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109433_bb0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0014-2999(83)90208-X","article-title":"Bromocriptine inhibits 2-deoxy-D-glucose-stimulated gastric acid secretion in the rat","volume":"90","author":"Maeda-Hagiwara","year":"1983","journal-title":"Eur. J. Pharmacol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825013136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825013136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T03:43:19Z","timestamp":1768966999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825013136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":43,"alternative-id":["S0045206825013136"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109433","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distribution- and metabolism-based drug discovery: SAR and SMR exploration of alkoxy-substituted vonoprazan derivatives as new potassium-competitive acid blockers","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109433","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109433"}}